NXP Semiconductors NV
Change company Symbol lookup
Select an option...
NXPI NXP Semiconductors NV
PRTK Paratek Pharmaceuticals Inc
VTR Ventas Inc
GBIM Globeimmune Inc
SCKT Socket Mobile Inc
BK Bank of New York Mellon Corp
BAC Bank of America Corp
AACG ATA Creativity Global
MDXL Medixall Group Inc
AMD Advanced Micro Devices Inc
Go

Information Technology : Semiconductors & Semiconductor Equipment | Large Cap Blend
Based in Netherlands
Company profile

NXP Semiconductors N.V. (NXP) is a holding company. The Company operates as a semiconductor company. The Company provides high performance mixed signal and standard product solutions. The Company's segments are High Performance Mixed Signal (HPMS), Standard Products (SP), and Corporate and Other. Its product solutions are used in a range of end-market applications, including automotive, personal security and identification, wireless and wireline infrastructure, mobile communications, multi-market industrial, consumer and computing. It engages with global original equipment manufacturers (OEMs) and sells products in all geographic regions. NXP's HPMS segment includes business lines, such as Automotive, Secure Identification Solutions (SIS), Secure Connected Devices (SCD), and Secure Interfaces and Infrastructure (SI&I). The Company's SP segment supplies a range of standard semiconductor components, such as small signal discretes and power discretes.

Price
Delayed
$137.70
Day's Change
0.47 (0.34%)
Bid
--
Ask
--
B/A Size
--
Day's High
138.85
Day's Low
137.02
Volume
(Light)

Today's volume of 367,807 shares is on pace to be much lighter than NXPI's 10-day average volume of 2,418,432 shares.

367,807

Walgreens stock falls after reporting $2 billion impairment due to COVID-19

7:49 am ET July 9, 2020 (MarketWatch)
Print

Walgreens Boots Alliance Inc. (WBA) stock fell 3.1% in Thursday premarket trading after the pharmacy retailer reported third-quarter earnings that missed expectations and reported a COVID-19-related sales impairment. Net loss totaled $1.71 billion, or $1.95 per share, after net income of $1.03 billion, or $1.13 per share, last year. Adjusted EPS of 83 cents fell short of the FactSet consensus for $1.19 per share. Sales of $34.63 billion were up slightly from $34.60 billion last year and ahead of the FactSet consensus for $34.30 billion. COVID-19 hurt Walgreens sales by $700 million to $750 million, which was almost entirely non-U.S. business. The most significant impact was in the U.K., where sales were down 85% in April and Walgreens took $2 billion in non-cash impairment charges. The results also reflect a 61-cent-to-65-cent per share operational impairment from the pandemic. The pharmacy business around the world was hurt by fewer doctor visits and hospital admissions. Prescriptions filled in the U.S. were down 1.3%, and U.S. retail same-store sales were up 1.9% due to increased demand for vitamins and personal protective equipment (PPE). "Shopping patterns are evolving more rapidly than ever as consumers further embrace digital options, spurring us to accelerate our ongoing investments in digital transformation and neighborhood health destinations," said Chief Executive Stefano Pessina in a statement. Those efforts include the expansion of the clinic collaboration with VillageMD and partnerships with Microsoft Corp. (MSFT) and Adobe Inc. (ADBE) for omnichannel service. Under the terms of the expanded deal with VillageMD, Walgreens will open 500 to 700 clinics in more than 30 markets over the next five years. Walgreens will invest $1 billion in equity and convertible debt in VillageMD over the next three years, with Walgreens holding 30% ownership interest in the company when the investment is complete. Walgreens completed a $250 million equity investment on Wednesday. Walgreens will close 48 Boots Opticians and cut office support headcount by 20% in U.K., impacting 4,000 jobs, or about 7% of the company's workforce. Walgreens expects 2020 adjusted EPS of $4.65 to $4.75, including $1.03 to $1.14 impact from COVID-19. The company forecasts additional impact from the pandemic in the fourth quarter. Walgreens raised its dividend 2.2% to 46.75 cents per share on Wednesday, payable Sept. 11, 2020 to shareholders of record as of Aug. 19 2020. Walgreens stock has tumbled 28.3% for the year to date while the S&P 500 index is down nearly 2% for the period.

-Tonya Garcia; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 09, 2020 07:49 ET (11:49 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.